Effect of Insulin Glargine combined with Repaglinide on hyperglycemia in patients with first-onset type 2 diabetes and its effect on islet β cell function
ZUO Lijuan1 LI Mingxia1 DENG Wenjuan1 GU Jun1 MA Hongwei2 REN Weidong1
1.Department of Endocrinology, the First Affiliated Hospital of Hebei North University, Hebei Province, Zhangjiakou 075000, China;
2.Department of Nuclear Medicine, the First Affiliated Hospital of Hebei North University, Hebei Province, Zhangjiakou 075000, China
Abstract：Objective To investigate the effect of Insulin Glargine combined with Repaglinide on hyperglycemia in patients with type 2 diabetes (T2DM). Methods Seventy-two patients with first-onset T2DM who were admitted to the First Affiliated Hospital of Hebei North University from February 2017 to December 2018 were selected and divided into combined group (Insulin Glargine + Repaglinide) and control group (premixed Insulin) according to random number table method, with 36 cases in each group. After 3 months of treatment, the blood glucose (fasting blood glucose [FBG], 2-hour postprandial blood glucose [2hPBG], glycated hemoglobin [HbA1c]), blood lipid (total cholesterol [TC], triglycerides [TG], and low density lipoprotein-cholesterol [LDL-C], high density lipoprotein-cholesterol [HDL-C]), inflammatory factors (interleukin-6 [IL-6], monocyte chemoattractant protein-1 [MCP-1], serum amyloid A [SAA]), islet β cell function indicators (fasting insulin [FINS], HOMA islet β cell function index [HOMA-β], HOMA insulin resistance index [HOMA-IR]) were compared between the two groups, and the occurrence of hypoglycemia was evaluated. Results After treatment, TC, TG, LDL-C levels decreased and HDL-C levels increased in the two groups, TC, TG, LDL-C levels in the combined group were lower than those in the control group, and HDL-C level was higher than the control group (all P ＜ 0.05). After treatment, serum IL-6, MCP-1, SAA levels decreased in the two groups, which in the combined group were lower than those in the control group (all P ＜ 0.05). After treatment, FBG, 2hPBG, and HbA1c levels were decreased in the two groups, which in the combined group were lower than those in the control group (all P ＜ 0.05). After treatment, FINS and HOMA-β increased with HOMA-IR decreased in the two groups, the combined group improved better than the control group (all P ＜ 0.05), and there was no significant difference in HOMA-IR between the two groups after treatment (P ＞ 0.05). The incidence of hypoglycemia in the combined group was lower than that in the control group (P ＜ 0.05), and there was no significant difference between the two groups in the rate of blood glucose reaching the standard (P ＞ 0.05). Conclusion For patients with first-onset T2DM with hyperglycemia, Insulin Glargine combined with Repaglinide has obvious effects on blood glucose and lipids, and can effectively protect islet β-cell function, inhibit inflammation, and reduce the incidence of hypoglycemia.
左丽娟1 李明霞1 邓文娟1 谷君1 马鸿伟2 任卫东1. 甘精胰岛素联合瑞格列奈改善高血糖状态的初发2型糖尿病患者效果以及对胰岛β细胞功能的影响[J]. 中国医药导报, 2020, 17(24): 71-74,92.
ZUO Lijuan1 LI Mingxia1 DENG Wenjuan1 GU Jun1 MA Hongwei2 REN Weidong1. Effect of Insulin Glargine combined with Repaglinide on hyperglycemia in patients with first-onset type 2 diabetes and its effect on islet β cell function. 中国医药导报, 2020, 17(24): 71-74,92.
2020, Vol. 17 
京公网安备 11010502046598号